Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
efalizumab · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| efalizumab | DRUG | - |
Inclusion criteria: * Clinical diagnosis of moderate to severe rheumatoid arthritis. * On stable dose of methotrexate. * 18 to 80 years of age. * Less than 275 lbs. Exclusion criteria: * Joint replacement surgery within 60 days of the start of drug dosing. * Intra-articular cortisone injections w...
Top 20 of 28 competitors
Efalizumab is an investigational immunology drug being studied for rheumatoid arthritis and psoriatic arthritis. It is a small molecule developed by XOMA Royalty Corporation (ticker: XOMA). The drug is currently in Phase 1 clinical development, with completed trials in both indications.
Efalizumab is a small molecule immunology drug. The specific molecular target of efalizumab has not been disclosed in available clinical trial information. It is being investigated for its potential effects in autoimmune conditions such as rheumatoid arthritis and psoriatic arthritis.
Efalizumab is developed by XOMA Royalty Corporation, which trades under the ticker XOMA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in rheumatoid arthritis and psoriatic arthritis.
Efalizumab is in Phase 1 clinical development. It has completed one Phase 1 trial in psoriatic arthritis and one Phase 2 trial in rheumatoid arthritis. The drug is investigational and has not been approved by regulatory authorities.
Efalizumab has been studied in two completed trials. NCT00034203 was a Phase 2 trial in rheumatoid arthritis, and NCT00051662 was a Phase 1 trial in psoriatic arthritis with 45 participants. Both trials were randomized and double-blind, though the control type was uncontrolled.
Efalizumab is also known by the brand name Raptiva. However, the available clinical trial data for efalizumab focuses on its use in rheumatoid arthritis and psoriatic arthritis, not on other conditions. The drug is being developed by XOMA Royalty Corporation.